Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99
PURPOSE: Immunosuppressive treatment is reported to improve cytopenia in some patients with myelodysplastic syndrome (MDS). Combined antithymocyte globulin (ATG) and cyclosporine (CSA) is most effective in patients with immune-mediated marrow failure. - PATIENTS AND METHODS: This trial was designed...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
Journal of clinical oncology
Year: 2011, Jahrgang: 29, Heft: 3, Pages: 303-309 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2010.31.2686 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2010.31.2686
|
| Verfasserangaben: | Jakob R. Passweg, Aristoteles A.N. Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf-Karsten Hofmann, Kristina Schilling, André Tichelli, Arnold Ganser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1817289659 | ||
| 003 | DE-627 | ||
| 005 | 20230710113956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220922s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2010.31.2686 |2 doi | |
| 035 | |a (DE-627)1817289659 | ||
| 035 | |a (DE-599)KXP1817289659 | ||
| 035 | |a (OCoLC)1389785311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Passweg, Jakob R. |d 1959- |e VerfasserIn |0 (DE-588)1077588011 |0 (DE-627)837268265 |0 (DE-576)446392251 |4 aut | |
| 245 | 1 | 0 | |a Immunosuppressive therapy for patients with myelodysplastic syndrome |b a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99 |c Jakob R. Passweg, Aristoteles A.N. Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf-Karsten Hofmann, Kristina Schilling, André Tichelli, Arnold Ganser |
| 264 | 1 | |c 2011 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online ahead of print on December 13, 2010 | ||
| 500 | |a Gesehen am 22.09.2022 | ||
| 520 | |a PURPOSE: Immunosuppressive treatment is reported to improve cytopenia in some patients with myelodysplastic syndrome (MDS). Combined antithymocyte globulin (ATG) and cyclosporine (CSA) is most effective in patients with immune-mediated marrow failure. - PATIENTS AND METHODS: This trial was designed to assess the impact of immunosuppression on hematopoiesis, transfusion requirements, transformation, and survival in patients with MDS randomly assigned to 15 mg/kg of horse ATG for 5 days and oral CSA for 180 days (ATG+CSA) or best supportive care (BSC), stratified by treatment center and International Prognostic Scoring System (IPSS) risk score. Primary end point was best hematologic response at 6 months. Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤ 2 and transfusion dependency of less than 2 years in duration. - RESULTS: Between 2000 and 2006, 45 patients received ATG+CSA (median age, 62 years; range, 23 to 75 years; 56% men) and 43 patients received BSC (median age, 65 years; range, 24 to 76 years; 81% men). IPSS score was low, intermediate-1, intermediate-2, high, and not evaluable in eight, 24, seven, one, and five patients on ATG+CSA, respectively, and eight, 25, five, zero, and five patients on BSC, respectively. Refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess of blasts (RAEB) -I, RAEB-II, and hypoplastic disease were present in 21, six, nine, zero, and nine patients on ATG+CSA, respectively, and 18, eight, 11, two, and four patients on BSC, respectively. By month 6, 13 of 45 patients on ATG+CSA had a hematologic response compared with four of 43 patients on BSC (P = .0156). Two-year transformation-free survival (TFS) rates were 46% (95% CI, 28% to 62%) and 55% (95% CI, 34% to 70%) for ATG+CSA and BSC patients, respectively (P = .730), whereas overall survival (OS) estimates were 49% (95% CI, 31% to 66%) and 63% (95% CI, 42% to 78%), respectively (P = .828). - CONCLUSION: This open-label randomized phase III trial demonstrates that ATG+CSA treatment seems to be associated with hematologic response in a subset of patients without apparent impact on TFS and OS. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Antilymphocyte Serum | |
| 650 | 4 | |a Cell Transformation, Neoplastic | |
| 650 | 4 | |a Cross-Over Studies | |
| 650 | 4 | |a Cyclosporine | |
| 650 | 4 | |a Drug Therapy, Combination | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Health Services | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Immunosuppressive Agents | |
| 650 | 4 | |a Intention to Treat Analysis | |
| 650 | 4 | |a Logistic Models | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Myelodysplastic Syndromes | |
| 650 | 4 | |a Prospective Studies | |
| 650 | 4 | |a Survival Analysis | |
| 700 | 1 | |a Giagounidis, Aristoteles |e VerfasserIn |0 (DE-588)172496160 |0 (DE-627)697433560 |0 (DE-576)133357066 |4 aut | |
| 700 | 1 | |a Simcock, Mathew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aul, Carlo |e VerfasserIn |0 (DE-588)1223054071 |0 (DE-627)1742391648 |4 aut | |
| 700 | 1 | |a Dobbelstein, Christiane |d 1975- |e VerfasserIn |0 (DE-588)173699936 |0 (DE-627)698606698 |0 (DE-576)134541561 |4 aut | |
| 700 | 1 | |a Stadler, Michael |d 1962- |e VerfasserIn |0 (DE-588)140678522 |0 (DE-627)62029714X |0 (DE-576)319386252 |4 aut | |
| 700 | 1 | |a Ossenkoppele, Gert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofmann, Wolf-Karsten |d 1967- |e VerfasserIn |0 (DE-588)114154635 |0 (DE-627)691208751 |0 (DE-576)351568336 |4 aut | |
| 700 | 1 | |a Schilling, Kristina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tichelli, André |e VerfasserIn |0 (DE-588)141323612 |0 (DE-627)626881900 |0 (DE-576)323331556 |4 aut | |
| 700 | 1 | |a Ganser, Arnold |d 1954- |e VerfasserIn |0 (DE-588)133814300 |0 (DE-627)556252268 |0 (DE-576)300124171 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 29(2011), 3, Seite 303-309 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Immunosuppressive therapy for patients with myelodysplastic syndrome a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99 |
| 773 | 1 | 8 | |g volume:29 |g year:2011 |g number:3 |g pages:303-309 |g extent:7 |a Immunosuppressive therapy for patients with myelodysplastic syndrome a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99 |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2010.31.2686 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220922 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 114154635 |a Hofmann, Wolf-Karsten |m 114154635:Hofmann, Wolf-Karsten |d 60000 |d 61200 |e 60000PH114154635 |e 61200PH114154635 |k 0/60000/ |k 1/60000/61200/ |p 8 | ||
| 999 | |a KXP-PPN1817289659 |e 4190907588 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"pubHistory":["1.1983 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"language":["eng"],"disp":"Immunosuppressive therapy for patients with myelodysplastic syndrome a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99Journal of clinical oncology","recId":"313116962","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"part":{"pages":"303-309","year":"2011","text":"29(2011), 3, Seite 303-309","volume":"29","issue":"3","extent":"7"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology"}],"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}]}],"note":["Published online ahead of print on December 13, 2010","Gesehen am 22.09.2022"],"physDesc":[{"extent":"7 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1817289659"],"doi":["10.1200/JCO.2010.31.2686"]},"language":["eng"],"title":[{"title":"Immunosuppressive therapy for patients with myelodysplastic syndrome","title_sort":"Immunosuppressive therapy for patients with myelodysplastic syndrome","subtitle":"a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99"}],"person":[{"role":"aut","given":"Jakob R.","display":"Passweg, Jakob R.","family":"Passweg"},{"display":"Giagounidis, Aristoteles","given":"Aristoteles","family":"Giagounidis","role":"aut"},{"role":"aut","family":"Simcock","display":"Simcock, Mathew","given":"Mathew"},{"role":"aut","family":"Aul","given":"Carlo","display":"Aul, Carlo"},{"family":"Dobbelstein","display":"Dobbelstein, Christiane","given":"Christiane","role":"aut"},{"family":"Stadler","display":"Stadler, Michael","given":"Michael","role":"aut"},{"display":"Ossenkoppele, Gert","given":"Gert","family":"Ossenkoppele","role":"aut"},{"role":"aut","family":"Hofmann","given":"Wolf-Karsten","display":"Hofmann, Wolf-Karsten"},{"role":"aut","family":"Schilling","display":"Schilling, Kristina","given":"Kristina"},{"role":"aut","given":"André","display":"Tichelli, André","family":"Tichelli"},{"role":"aut","given":"Arnold","display":"Ganser, Arnold","family":"Ganser"}],"recId":"1817289659","origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"2011"}],"name":{"displayForm":["Jakob R. Passweg, Aristoteles A.N. Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf-Karsten Hofmann, Kristina Schilling, André Tichelli, Arnold Ganser"]}} | ||
| SRT | |a PASSWEGJAKIMMUNOSUPP2011 | ||